<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115942</url>
  </required_header>
  <id_info>
    <org_study_id>KDN-F351-202101</org_study_id>
    <nct_id>NCT05115942</nct_id>
  </id_info>
  <brief_title>Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Viral Hepatitis B Phase 3 Trial.</brief_title>
  <official_title>Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Hepatitis B:Randomized,Double-blind,Placebo-controlled,Entecavir Basic Treatment,Multicentre Phase 3 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment,&#xD;
      multicentre clinical study.&#xD;
&#xD;
      The main objective of this study was to confirm the efficacy and safety of hydronidone in the&#xD;
      treatment of chronic hepatitis B liver fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      248 patients with chronic viral hepatitis B liver fibrosis were enrolled in this 52-week&#xD;
      study, and randomized into hydronidone or placebo group. Each group has 124 subjects. Both&#xD;
      groups were treated with entecavir antiviral basic therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological score of Ishak stage</measure>
    <time_frame>52 weeks</time_frame>
    <description>After 52 weeks of treatment, the proportion of Ishak of liver fibrosis decreased by more than 1 point from baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Hydronidone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were given three capsules of hydronidone three times a day for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were given three capsules of placebo three times a day for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydronidone capsules</intervention_name>
    <description>After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 52 weeks.</description>
    <arm_group_label>Hydronidone group</arm_group_label>
    <other_name>F351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The placebo capsules</intervention_name>
    <description>After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 52 weeks.</description>
    <arm_group_label>The placebo group</arm_group_label>
    <other_name>N</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 65 years old (including 18 and 65 years old, based on the time of&#xD;
             signing the written informed consent); gender is not limited.&#xD;
&#xD;
          2. History of chronic hepatitis B and/or hepatitis B surface antigen (HBsAg) positive≥6&#xD;
             months.&#xD;
&#xD;
          3. Percutaneous liver biopsy confirmed liver fibrosis (Ishak score ≥3).&#xD;
&#xD;
          4. Positive HBV DNA.&#xD;
&#xD;
          5. ALT &lt; 8 x ULN (standard upper limit).&#xD;
&#xD;
          6. No antiviral therapy with interferon and/or nucleoside analogues within 3 months prior&#xD;
             to enrollment.&#xD;
&#xD;
          7. 3 months before inclusion, he/she had not received any of the following proprietary&#xD;
             Chinese medicines that may have anti-fibrosis effects: Fuzheng Huayu Capsule (tablet),&#xD;
             Anluo Huayu Pill, compound Bijiaruangan tablet, etc.&#xD;
&#xD;
          8. The subject (or his/her sexual partner) had no pregnancy plan during the trial period&#xD;
             and within 6 months after the trial, voluntarily used effective physical&#xD;
             contraception, and had no sperm or egg donation plan.&#xD;
&#xD;
          9. Before the trial, they have understood the nature, significance, potential benefits,&#xD;
             inconvenience and potential dangers of the trial in detail, and have voluntarily&#xD;
             participated in the clinical trial, have good communication with the researchers,&#xD;
             comply with the requirements of the whole study, and have signed a written informed&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Massive upper gastrointestinal hemorrhage within 3 months before enrolment.&#xD;
&#xD;
          2. Total bilirubin (TBIL) &gt; 3×ULN, or 3×ULN &lt; ALT &lt; 8×ULN and TBIL &gt; 2×ULN.&#xD;
&#xD;
          3. AFP &gt; 100 μg/L although there was no indication of liver cancer.&#xD;
&#xD;
          4. Platelets (PLT) ≤60×109/L.&#xD;
&#xD;
          5. Prothrombin activity (PTA) &lt; 50% or INR &gt; 1.5.&#xD;
&#xD;
          6. Imaging showed obvious space-occupying lesions in the liver, suggesting tumor.&#xD;
&#xD;
          7. Body mass index (BMI) &gt; 30 kg/m2.&#xD;
&#xD;
          8. Patients with decompensated liver cirrhosis and liver malignant tumor.&#xD;
&#xD;
          9. Patients with chronic hepatitis C or non-viral (alcoholic, non-alcoholic, drug, etc.)&#xD;
             chronic hepatitis.&#xD;
&#xD;
         10. Serious diseases of cardiovascular, pulmonary, renal, endocrine, neurological and&#xD;
             haematological systems, as well as mental disorders .&#xD;
&#xD;
         11. Women who are pregnant and/or breastfeeding.&#xD;
&#xD;
         12. Have participated in clinical trials of other drugs in the last 3 months.&#xD;
&#xD;
         13. The Investigator considers that there are any conditions that may affect the subjects'&#xD;
             informed consent or adherence to the study protocol, or participation in the study may&#xD;
             affect the study results or their own safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lungen Lu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Cheng, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Ditan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Zhang, Dr.</last_name>
    <phone>+86-13501209210</phone>
    <email>zhangling@bjcontinent.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

